Impact of anti-TNF and anti-IL-12/IL-23 antibody therapy on periodontal inflammation and gingival crevicular fluid IL-6 in patients with inflammatory bowel diseases - Scorecard - MDSpire
Advertisement
Impact of anti-TNF and anti-IL-12/IL-23 antibody therapy on periodontal inflammation and gingival crevicular fluid IL-6 in patients with inflammatory bowel diseases
Clinical Scorecard: Effects of Anti-TNF and Anti-IL-12/IL-23 Antibody Treatments on Periodontal Inflammation and IL-6 Levels in Gingival Crevicular Fluid Among Inflammatory Bowel Disease Patients
At a Glance
Category
Detail
Condition
Periodontitis in Inflammatory Bowel Disease (IBD)
Key Mechanisms
Cytokine modulation, specifically targeting TNF and IL-12/23 pathways.
Target Population
Patients with inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis.
Care Setting
Clinical assessment of periodontal health in IBD patients.
Key Highlights
remove
Guideline-Based Recommendations
Diagnosis
Periodontal status assessed using the Periodontal Screening Index (PSI).
Management
Consider cytokine-targeted therapies in IBD management to potentially influence periodontal disease.
Monitoring & Follow-up
Monitor IL-6 levels in gingival crevicular fluid as a marker of local inflammation.
Risks
Increased susceptibility to periodontitis in patients with IBD.
Patient & Prescribing Data
Patients with inflammatory bowel diseases (IBD) undergoing biological therapy.
Anti-IL-12/23 therapy may reduce periodontal inflammatory burden.
Clinical Best Practices
Regular periodontal assessments for patients with IBD.
Consideration of oral health in the management of IBD.
